Brief: Grifols Achieves Self-Sufficiency In Plasma-Derived Medicines In Egypt
Dec 4 (Reuters) - Grifols SA GRLS.MC: THROUGH GRIFOLS EGYPT FOR PLASMA DERIVATIVES (GEPD), HAS ACHIEVED CLINICAL SELF-SUFFICIENCY IN IMMUNOGLOBULINS, ALBUMIN, AND COAGULATION FACTORS FOR BLEEDING DISORDERS CO CURRENTLY HAS 16 DONATION CENTRES IN EGYPT, WITH FOUR MORE TO BE ADDED IN 2026 Source text Further company coverage: GRLS.MC (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com;))
Recent news on Grifols SA
See all newsSpanish stocks - Factors to watch on June 24
Brief: Grifols Approves Reduction Of Up To 10% Of Its Share Capital
Brief: Grifols Launches Fibrinogen Concentrate For Acute Bleeding Episodes In The U.S.
Brief: Grifols' Egypt Unit Adds €180 Mln Of Additional Investment In Project
Spanish stocks - Factors to watch on June 12